Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists

Drugs and Aging

Volumn 9, Issue 4, 1996, Pages 251-261

  Lazzaroni, Marco ^a   Porro, Gabriele Blanchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORDIAZEPOXIDE; CIMETIDINE; DIAZEPAM; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LIDOCAINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; RANITIDINE; THEOPHYLLINE; WARFARIN;

AGED; DRUG TOLERABILITY; GERIATRICS; HEADACHE; HEART ARRHYTHMIA; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; ULCER HEALING; VERTIGO;

EID: 0029954180     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609040-00003     Document Type: Review

References (72)

1. Bozymski EM, Isaacs KL. Special diagnostic and therapeutic considerations in elderly patients with upper gastrointestinal disease. Clin Gastroenterol 1991; 13 Suppl. 2: S65-75
2. Kurata JH, Haile BM, Elashoff JD. Sex differences in peptic ulcer disease. Gastroenterology 1985; 88: 96-100
3. Collier DSJ, Pain JA. Nonsteroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 1985; 26: 359-63
4. Lamy PP. A consideration of NSAID use in the elderly. Geriatr Med Today 1988; 7: 1-11
5. Lamy PP. Physiological changes due to age: pharmacodynamic changes of drug action and implications for therapy. Drugs Aging 1991; 1: 385-404
6. Krentz K, Jablonowski H. Functional and histological gastric changes with age. In: Hellemans J, VanTrappen G, editors. Gastrointestinal tract disorders in the elderly. Edinburgh: Churchill Livingstone, 1984: 62-9
7. Pilotto A, Vianello F, DiMario F, et al. Effect of age on gastric acid, pepsin, pepsinogen group A. and gastrin secretion in peptic ulcer patients. Gerontology 1994; 40: 253-9
8. Farinati F, Formentini S, Della Libera G, et al. Changes in parietal and mucous cell mass in the gastric mucosa of normal subjects with age: a morphometric study. Gerontology 1993; 39: 146-51
9. Goldschmiedt M, Barnett CC, Schwarz BE, et al. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterology 1991; 101: 977-90
10. Cryer B, Redfern JS, Lee E, et al. Decline in gastroduodenal mucosal prostaglandins with aging in humans: relationship with gastric acid secretion [abstract]. Gastroenterology 1991; 100: 427A
11. Pilotto A. Gastric ulcer in the elderly. Ital J Gastroenterol 1994; 26 Suppl. 1: 10-5
12. Beers M, Ouslander J. Risk factors in geriatric drug prescribing: a practical guide to avoiding problems. Drugs 1989; 37: 105-12
13. Parkin DM, Henry CR, Quirk J, et al. Deviation from prescribed drug treatment after discharge from hospital. BMJ 1976; 2: 686-8
14. Stewart RB. Noncompliance in the elderly: is there a cure? Drugs Aging 1991; 1: 163-7
15. Chiverton SG, Hunt RH. Pharmacokinetics and pharmacodynamics of treatments for peptic ulcer disease in the elderly. Am J Gastroenterol 1988; 83: 211-5
16. Okada M, Yao K, Fuchigami T, et al. Factors influencing the healing rates of gastric ulcer in hospitalized patients. Gut 1984; 25: 881-5
17. Wright JP, Marks IN, Mee AS, et al. Ranitidine in the treatment of gastric ulcer. Afr Med J 1982; 61: 155-8
18. Herman RP, Piper DW. Factors influencing the healing rate of chronic gastric ulcer. Am J Dig Dis 1973; 1: 1-6
19. Sonnenberg A, Muller-Lissner SA, Vogel E, et al. Predictors of duodenal ulcer healing and relapse. Gastroenterology 1981; 81: 1061-7
20. Bianchi Porro G, Lazzaroni M. Prescribing policy for antiulcer treatment in the elderly. Drugs Aging 1993; 3: 308-19
21. Mills RJ, Begun JM, Holland CE, et al. Ranitidine for duodenal ulcer disease in the elderly: a retrospective review of four multicentre trials. Geriatr Drug Ther 1988; 3: 43-6
22. Tam HC, Lee YC, Wong HY, et al. Healing of gastric ulcer in the elderly: a double blind study of cetraxate versus ranitidine. Clin Gastroenterol 1989; 11: 183-6
23. Battaglia G, Di Mario F, Vio A, et al. H: blockers in the treatment of ulcer disease in the elderly. Adv Ther 1990; 7: 78-85
24. Battaglia G, Di Mario F, Vigneri S, et al. Peptic ulcer in the elderly - a double blind, short term study comparing nizatidine 300 mg with ranitidine 300 mg. Aliment Pharmacol Ther 1993; 7: 643-8
25. Battaglia F, Di Mario F, Dotto P, et al. Markers of slow healing peptic ulcer in the elderly: a study on 1052 ranitidine treated patients. Dig Dis Sci 1993; 8: 1414-21
26. Ehsanullah RSB, Mills J, Wood JR. Use of ranitidine to treat duodenal ulceration in the elderly [abstract]. Gastroenterology 1991; 100: A58
27. Dickinson RJ, Royston CMS, Sutton DR. A comparison of famotidine and ranitidine in an elderly population: a multicentre study. Postgrad Med J 1988; 62 Suppl. 2: 63-5
28. Howden CW, Jones DB, Peace KE, et al. The treatment of gastric ulcer with antisecretory drugs: relationship of pharmacological effect to healing rate. Dig Dis Sci 1988; 33: 619-24
29. Bianchi Porro G, Lazzaroni M. Peptic ulcer disease: medical treatment. In: Gustavsson S, Kumar D, Graham DY, editors. The stomach. New York: Churchill Livingstone, 1992: 246-65
30. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on long term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116: 703-8
31. DiMario F, Leandro G, Battaglia G, et al. Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly? Dig Dis Sci 1996; 41: 17-21
32. Cedeberg C, Anderson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 Suppl. 166: 36-42
33. Lind T, Cedeberg C, Olausson M, et al. Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and plasma fasting gastrin. Eur J Clin Pharmacol 1991; 40: 557-60
34. Walan A. Therapy with omeprazole, an acid pump inhibitor. In: Swab EA, Szabo S, editors. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 217-30
35. Pilotto A, Di Mario F, Battaglia G, et al. The efficacy of two doses of omeprazole for short and long term peptic ulcer treatment in the elderly. Clin Ther 1994; 6: 935-41
36. Murakami M, Saita H, Takahashi Y, et al. Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. Clin Gastroenterol 1995; 20 Suppl. 2: S79-82
37. Bianchi Porro G, Lazzaroni M. Prevention and treatment of nonsteroidal gastroduodenal lesions. Eur J Gastroenterol Hepatol 1993; 5: 420-32
38. Lancaster Smith MJ, Jadeberg ME, Jackson DA. Ranitidine in the treatment of nonsteroidal antiinflammatory drug associated gastric and duodenal ulcer. Gut 1991; 32: 252-5
39. Walan A, Bader JP, Classem M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69-75
40. Bank S, Greenberg RE, Magier D, et al. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin related ulcers. Clin Ther 1991; 13: 304-18
41. Bank S, Zucker S, Greenberg RE, et al. Effect of famotidine on gastric ulcer healing: a comparison between nonsteroidal and aspirin-induced ulceration and idiopathic ulcers [abstract]. Am J Gastroenterol 1991; 86: 1308
42. Darle N, Almskog B, Bergegardh S, et al. Treatment of acute massive gastroduodenal haemorrhage with cimetidine in elderly patients. Ann Chir Gynaecol 1984; 73: 64-8
43. Steinheber FU. Ageing and the stomach. Clin Gastroenterol 1985; 14: 657-88
44. Drayer DS, Romankiewicz J, Lorenzo B, et al. Age and renal clearance of cimetidine. Clin Pharmacol Ther 1982; 31: 45-50
45. Young CJ, Daneshmend TK, Roberts CJC. Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. Gut 1982; 23: 814-23
46. Greene DS, Szego PL, Anslow JA, et al. The effect of age on ranitidine pharmacokinetics. Clin Pharmacol Ther 1986; 39: 300-5
47. Inotsume N, Nishimura N, Fujyiama S, et al. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers. Eur J Clin Pharmacol 1989; 36: 517-20
48. Lin JH, Chremos AN, Yeh KC, et al. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988; 34: 41-6
49. 2 receptor antagonist: disposition and safety in the elderly. Clin Pharmacol 1987; 27: 618-24
50. Ritschel WA. Cimetidine dosage regimen for patients with renal failure and for geriatrics patients. Eur J Clin Pharmacol 1982; 23: 501-4
51. Sorkin EM, Darvey DL. Review of cimetidine drug interactions. Drug Intell Clin Pharm 1983; 17: 110-20
52. Mitchard M. Ranitidine drug interactions: a literature review. Pharmacol Ther 1987; 32: 293-325
53. Langtry HD, Grant SM, Goa KL. Famotidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 38: 551-90
54. Price AH, Brogden RN. Nizatidine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 521-39
55. Murdoch D, McTavish D. Roxatidine acetate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs 1991; 42: 240-60
56. Hennan NE, Carpenter DU, Janda SM. Famotidine associated mental contusion in elderly patients. Drug Intell Clin Pharm 1988; 22: 976-8
57. Solvell L. The clinical safety of omeprazole. Scand J Gastroenterol 1989; 24 Suppl. 166: 106-10
58. Pilotto A, Franceschi M, Lagni M. The effect of omeprazole on serum concentrations of theophylline, pepsinogens A and C, and gastrin in elderly duodenal ulcer patients. Am J Ther 1995; 2: 43-6
59. Howden CW, Reid JL. The effect of antacids and metoclopramide on omeprazole absorption and disposition. Br J Clin Pharmacol 1988; 25: 779-80
60. Delhotal-Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and distribution. Eur J Drug Metab Pharmacokinet 1991; Special Issue III: 315-20
61. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91
62. Bardhan KD, Hinchliffe RFC, Bose K, et al. Six years of continuous cimetidine treatment in peptic ulcer disease: efficacy and safety. Aliment Pharmacol Ther 1988; 2: 395-405
63. Penston J, Wormsley KG. Efficacy and safety of long term maintenance therapy of duodenal ulcers. Scand J Gastroenterol 1989; 24: 1145-52
64. Walan A, Bianchi Porro G, Hentschel E, et al. Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397-405
65. Lee FI, Hardman M, Jadeberg ME. Maintenance treatment of duodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers. Gut 1991; 32: 151-3
66. Pilotto A, Di Mario F, Battaglia G, et al. Efficacy and safety of peptic ulcer long term therapy in the elderly: a double blind multicentre, one year study. In: Beregi E, Gergely LA, Rajczi K, editors. Recent advances in aging science. Bologna: Monduzzi, 1993: 1133-6
67. Tytgat GNJ, Dixon MF. Role of Helicobacter pylori in the pathogenesis of peptic ulcer disease: practical implications for the clinician. In: Hunt RH, editor. Proton pump inhibitors and acid related disorders. Osaka: Adis International, 1994: 79-100
68. NIH consensus conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 1972: 65-9
69. Faisal MA, Russel RM, Smaloff IM, et al. Helicobacter pylori infection and atrophic gastritis in the elderly. Gastroenterology 1990; 99: 1543-4
70. Safe AF, Warren B, Corfield A, et al. Helicobacter pylori infection in elderly people: correlation between histology and serology. Age Ageing 1993; 22: 215-20
71. Gilinsky NH. Peptic ulcer disease in the elderly. Scand J Gastroenterol 1988; 23 Suppl. 146: 191-200
72. Jenike MA. Cimetidine in elderly patients: review of uses and risks. Am Geriatr Soc 1982; 30: 170-3